Gedeon Richter PLC (GEDSF)
ValueMarkers Composite Index
69% below intrinsic value ($0)
Gedeon Richter PLC (GEDSF) — VMCI valuation read
Headline read on GEDSF: VMCI of 71/100 versus a Healthcare sector median of 50. The 21-point above-median position is what makes Gedeon Richter PLC a relative-value candidate in the mid-cap cohort, before any pillar-level review.
Form 4 filings on GEDSF: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.
**Investor frame.** Three reads on GEDSF: value (GEDSF trades at 17.0x earnings, 6% below the Healthcare median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 2.2x is the rate-sensitivity line to watch). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.
GEDSF fell 4.0% over the trailing 7 days, with a -6.3% read on a 30-day basis.
Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. It operates through the following segments: Pharmaceuticals, Wholesale & Retail, and Others. The Pharmaceutical segment engages in research and development, manufacturing, sales and marketing of pharmaceutical products. The Wholesale & Retail segment represents the distribution of companies and pharmacies that are part of the sales network in various regional markets and, as such, convey its products to consumers. The Other segment relates to the business of the members of the group that provide marketing and sales support services. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.